Notícias Allogene Therapeutics Inc - ALLO | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allogene Therapeutics Inc (ALLO)
Allogene Therapeutics Inc (ALLO) Notícias

Allogene Therapeutics Inc (ALLO)

1,95

0,08

(4,28%)

No fechamento: 23 Dezembro 6:00PM

Atrasado por 15 minutos

1,95

0,00

( 0,00% )

Após o horário de negociação: 6:30PM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy

Allogene Therapeutics Announces Participation in November Investor Conferences

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Allogene Therapeutics

Global X Fintech UCITS E...

ETFS Long NOK Short EUR

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições